Pyridinophane Ligands: Manganese Chelator Properties for MRI and PET Imaging

Manganese-based magnetic resonance imaging contrast agents were developed using chelators derived from the 2,11-diaza[3.3](2,6)pyridinophane macrocycle. The dataset likely contains synthesized chelator properties, with two compounds showing potential: [Mn(TE-1)] exhibited relaxivity of 3.6 mM–1 s–1 at 1.4 T, and [Mn(TE-4)] displayed rapid renal clearance. The data was authored by Tarek El Sayed and last updated on 2026-05-21.

Use Cases

• Evaluating chelator design for manganese-based MRI contrast agents based on coordination number and pendant arm selection described in the study.
• Comparing relaxivity performance of novel agents against clinical gadolinium-based standards, referencing the 3.6 mM–1 s–1 measurement.
• Assessing pharmacokinetic properties like renal or biliary excretion for imaging agent development, based on the in vivo PET imaging results.

Strengths

• Includes specific quantitative results, such as a relaxivity measurement of 3.6 mM–1 s–1 at 1.4 T.
• Describes in vivo validation of agent behavior via PET imaging with ⁵²Mn.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 556.0 B, indicating limited scope.

Provenance

Source

figshare

Collection Method

Likely contains experimental results from the synthesis and assessment of chelators.

Freshness

Last updated 2026-05-21 09:26:28; freshness should be verified.